Advertisement

Clinical Pharmacokinetics

, Volume 42, Issue 15, pp 1319–1330 | Cite as

Bone-Specific Drug Delivery Systems

Approaches via Chemical Modification of Bone-Seeking Agents
  • Hideki Hirabayashi
  • Jiro Fujisaki
Leading Article

Abstract

Despite several decades of progress, bone-specific delivery is still limited by the unique anatomical features of bone, which mainly consists of inorganic hydroxyapatite. A practical approach to this problem is to produce targeted drugs that have a high affinity for hydroxyapatite. Bisphosphonates are a class of synthetic compounds structurally related to pyrophosphate. Bisphosphonates rapidly localise on the bone surface after being administered either intravenously or orally, since the P-C-P portion of the bisphosphonate structure has high affinity for hydroxyapatite. Therefore, bisphosphonate modification might be a promising method for targeting drugs selectively to the bone.

Bisphosphonate-conjugated drugs are hydrophilic and highly water-soluble due to the acidic nature of the bisphosphonate moiety at physiological pH, and therefore they hardly permeate through the biological membrane of soft tissues. These physicochemical changes also reduce the intrinsic susceptibility of the drug to metabolism, promoting urinary or biliary excretion as unchanged drug. All these physicochemical and pharmacokinetic alterations contribute to the exceptional skeletal disposition of bisphosphonate-conjugated drugs.

Bisphosphonate conjugation is based on chemical modification of the targeting molecule, and therapeutically optimised bisphosphonate derivatives have to be custom-developed on a case-by-case basis. The bisphosphonate moiety is usually coupled with the targeting drug through a specific linkage. The high affinity of bisphosphonate conjugates for the bone is not simply dependent on the bisphosphonate moiety but on the resultant molecule as a whole, including the linker and the linked drug. Lipophilicity (represented as log P) appears to be an appropriate index for predicting the osteotropic properties of bisphosphonate derivatives.

Several strategies using bisphosphonate-conjugated drugs have been investigated at a laboratory level with the aim of obtaining therapeutically optimised treatments for conditions such as osteoporosis, osteoarthritis and bone cancer. In each case, the intention is to achieve prolonged local exposure to high concentrations of the targeting drug, thereby improving therapeutic index by enhancing pharmacological efficacy and minimising systemic adverse effects.

Although most examples of bone-specific drug delivery via bone-seeking agents still remain in preclinical studies, several phosphonate-coupled radiopharmaceuticals, such as samarium-153 complexed to tetraphosphonate, are expected to be an effective pain palliation therapies for metastatic bone cancer and are currently being developed in clinical trials. Furthermore, recent reports on bisphosphonate-modified proteins have illustrated the feasibility of bone-specific delivery of biologically active protein drugs, such as cytokines and growth factors.

Keywords

Estradiol Bisphosphonate Biliary Excretion Systemic Adverse Effect Uterine Weight 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

Financial support for this manuscript was provided by Fujisawa Pharmaceutical Co. Ltd. The authors wish to thank Bindu Gadani, M.S., for critical reading and reviewing of the manuscript. The authors have no conflicts of interest that are directly relevant to the content of this manuscript.

References

  1. 1.
    Abbott III TA, Lawrence BJ, Wallach S. Osteoporosis: the need for comprehensive treatment guidelines. Clin Ther 1996; 18(1): 127–49PubMedCrossRefGoogle Scholar
  2. 2.
    Hoerger TJ, Downs KE, Lakshmanan MC, et al. Healthcare use among US women aged 45 and older: total costs and costs for selected postmenopausal health risks. J Womens Health Gend Based Med 1999; 8(8): 1077–89PubMedCrossRefGoogle Scholar
  3. 3.
    Tahara Y, Ishii Y. Apatite cement containing cis-diamminedichloroplatinum implanted in rabbit femur for sustained release of the anticancer drug and bone formation. J Orthop Sci 2001; 6(6): 556–65PubMedCrossRefGoogle Scholar
  4. 4.
    Kato H, Neo M, Tamura J, et al. Bone bonding in bioactive glass ceramics combined with a new synthesized agent TAK-778. J Biomed Mater Res 2001; 57(2): 291–9PubMedCrossRefGoogle Scholar
  5. 5.
    Sánchez E, Baro M, Soriano I, et al. In vivo-in vitro study of biodegradable and osteointegrable gentamicin bone implants. Eur J Pharm Biopharm 2001; 52(2): 151–8PubMedCrossRefGoogle Scholar
  6. 6.
    Woo BH, Fink BF, Page R, et al. Enhancement of bone growth by sustained delivery of recombinant human bone morphogenetic protein-2 in a polymeric matrix. Pharm Res 2001; 18(12): 1747–53PubMedCrossRefGoogle Scholar
  7. 7.
    Talmage RV. Morphological and physiological consideration in a new concept of calcium transport in bone. Am J Anat 1970; 129(4): 467–76PubMedCrossRefGoogle Scholar
  8. 8.
    Lin JH. Bisphosphonates: a review of their pharmacokinetic properties. Bone 1996; 18(2): 75–85PubMedCrossRefGoogle Scholar
  9. 9.
    Cantrill JA, Anderson DC. Treatment of Pagets’s disease of bone. Clin Endocrinol (Oxf) 1990; 32(4): 507–18CrossRefGoogle Scholar
  10. 10.
    Heath D. The treatment of hypercalcaemia of malignancy. Clin Endocrinol (Oxf) 1991; 34(2): 155–7CrossRefGoogle Scholar
  11. 11.
    van Holten-Verzantvoort AT, Bijvoet OL, Cleton FJ, et al. Reduced morbidity from skeletal metastases in breast cancer patients during long-term bisphosphonate (APD) treatment. Lancet 1987; II (8566): 983–5CrossRefGoogle Scholar
  12. 12.
    Storm T, Thamsborg G, Steiniche T, et al. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 1990; 322(18): 1265–71PubMedCrossRefGoogle Scholar
  13. 13.
    Myers HM. Structure-activity relationships (SAR) of hydroxyapatite-binding molecules. Calcif Tissue Int 1987; 40(6): 344–8PubMedCrossRefGoogle Scholar
  14. 14.
    Bisaz S, Jung A, Fleisch H. Uptake by bone of pyrophosphate, diphosphonates and their technetium derivatives. Clin Sci Mol Med 1978; 54(3): 265–72PubMedGoogle Scholar
  15. 15.
    Fleisch H. Bisphosphonates: a new class of drugs in diseases of bone and calcium metabolism. In: Baker PF, editor. Handbook of experimental pharmacology. Vol. 83. Berlin-Heidelberg: Springer, 1988: 441–66Google Scholar
  16. 16.
    Fujisaki J, Tokunaga Y, Takahashi T, et al. Osteotropic drug delivery system (ODDS) based on bisphosphonic prodrug. I: synthesis and in vivo characterization of osteotropic carboxyfluorescein. J Drug Target 1995; 3(4): 273–82PubMedCrossRefGoogle Scholar
  17. 17.
    Tsushima N, Yabuki M, Harada H, et al. Tissue distribution and pharmacological potential of SM-16896, a novel oestrogenbisphosphonate hybrid compound. J Pharm Pharmacol 2000; 52(1): 27–37PubMedCrossRefGoogle Scholar
  18. 18.
    Hirabayashi H, Takahashi T, Fujisaki J, et al. Bone-specific delivery and sustained release of diclofenac, a non-steroidal anti-inflammatory drug, via bisphosphonic prodrug based on the Osteotropic Drug Delivery System (ODDS). J Control Release 2001; 70 (1–2): 183–91PubMedCrossRefGoogle Scholar
  19. 19.
    Boulenc X, Marti E, Joyeux H, et al. Importance of the paracellular pathway for the transport of a new bisphosphonate using the human CACO-2 monolayers model. Biochem Pharmacol 1993; 46(9): 1591–600PubMedCrossRefGoogle Scholar
  20. 20.
    Lin JH, Chen I-W, de Luna FA, et al. Effects of dose, sex, and age on the disposition of alendronate, a potent antiosteolytic bisphosphonate, in rats. Drug Metab Dispos 1992; 20(4): 473–8PubMedGoogle Scholar
  21. 21.
    Lin JH, Duggan DE, Chen I-W, et al. Physiological disposition of alendronate, a potent anti-osteolytic bisphosphonate, in laboratory animals. Drug Metab Dispos 1991; 19(5): 926–32PubMedGoogle Scholar
  22. 22.
    Fujisaki J, Tokunaga Y, Takahashi T, et al. Physicochemical characterization of bisphosphonic carboxyfluorescein for osteotropic drug delivery. J Pharm Pharmacol 1996; 48(8): 798–800PubMedCrossRefGoogle Scholar
  23. 23.
    Fujisaki J, Tokunaga Y, Sawamoto T, et al. Osteotropic drug delivery system (ODDS) based on bisphosphonic prodrug. III: pharmacokinetics and targeting characteristics of osteotropic carboxyfluorescein. J Drug Target 1996; 4(2): 117–23PubMedCrossRefGoogle Scholar
  24. 24.
    Smith RL. Excretion of drugs in bile. In: Brodie BB, Gillette JR, editors. Handbook of experimental pharmacology: concepts in biochemical pharmacology. Vol. 28. Berlin: Springer, 1971: 354–89CrossRefGoogle Scholar
  25. 25.
    Mönkkönen J, Urtti A, Paronen P, et al. The uptake of clodronate (dichloromethylene bisphosphonate) by macrophages in vivo and in vitro. Drug Metab Dispos 1989; 17(6): 690–3PubMedGoogle Scholar
  26. 26.
    Mönkkönen J, Ylitalo P. The tissue distribution of clodronate (dichloromethylene bisphosphonate) in mice: the effects of vehicle and the route of administration. Eur J Drug Metab Pharmacokinet 1990; 15(3): 239–43PubMedCrossRefGoogle Scholar
  27. 27.
    Mönkkönen J, Rooijen N, Ylitalo P. Effects of clodronate and pamidronate on splenic and hepatic phagocytic cells of mice. Pharmacol Toxicol 1991; 68(4): 284–6PubMedCrossRefGoogle Scholar
  28. 28.
    Hirabayashi H, Sawamoto T, Fujisaki J, et al. Dose dependent pharmacokinetics and disposition of bisphosphonic prodrug of diclofenac based on Osteotropic Drug Delivery System (ODDS). Biopharm Drug Dispos 2002; 23(8): 307–15PubMedCrossRefGoogle Scholar
  29. 29.
    Hirabayashi H, Sawamoto T, Fujisaki J, et al. Relationship between physicochemical and osteotropic properties of bisphosphonic derivatives: rational design for osteotropic drug delivery system (ODDS). Pharm Res 2001; 18(5): 646–51PubMedCrossRefGoogle Scholar
  30. 30.
    Fleisch H. Diphosphonates: history and mechanisms of action. Metab Bone Dis Relat Res 1981; 3 (4–5): 279–87PubMedCrossRefGoogle Scholar
  31. 31.
    van Beek E, Hoekstra M, van de Ruit M, et al. Structure requirement of bisphosphonate actions in vitro. J Bone Miner Res 1994; 9(12): 1875–82PubMedCrossRefGoogle Scholar
  32. 32.
    Sunberg R, Ebetino FH, Mosher CT, et al. Designing drugs for stronger bones. Chemtech 1991; 21: 304–9Google Scholar
  33. 33.
    Cohen H, Solomon V, Alferiev IS, et al. Bisphosphonates and tetracycline: experimental models for their evaluation in calcium-related disorders. Pharm Res 1998; 15(4): 606–13PubMedCrossRefGoogle Scholar
  34. 34.
    Cohen H, Alferiev IS, Mönkkönen J, et al. Synthesis and preclinical pharmacology of 2-(2-aminopyrimidinio) ethylene-1,1-bisphosphonic acid betaine (ISA-13-1), a novel bisphosphonate. Pharm Res 1999; 16(9): 1399–406PubMedCrossRefGoogle Scholar
  35. 35.
    Hoffman A, Stepensky D, Ezra A, et al. Mode of administration-dependent pharmacokinetics of bisphosphonate and bio-availability determination. Int J Pharm 2001; 220 (1–2): 1–11PubMedCrossRefGoogle Scholar
  36. 36.
    Gil L, Han Y, Opas EE, et al. Prostaglandin E2-bisphosphonate conjugates: potential agents for treatment of osteoporosis. Bioorg Med Chem 1999; 7(5): 901–19PubMedCrossRefGoogle Scholar
  37. 37.
    Bauss F, Esswein A, Reiff K, et al. Effect of 17β-estradiol-bisphosphonate conjugates, potential bone-seeking estrogen pro-drugs, on 17β-estradiol serum kinetics and bone mass in rats. Calcif Tissue Int 1996; 59(3): 168–73PubMedCrossRefGoogle Scholar
  38. 38.
    Fujisaki J, Tokunaga Y, Takahashi T, et al. Osteotropic drug delivery system (ODDS) based on bisphosphonic prodrug. IV: effects of osteotropic estradiol on bone mineral density and uterine weight in ovariectomized rats. J Drug Target 1998; 5(2): 129–38PubMedCrossRefGoogle Scholar
  39. 39.
    Fujisaki J, Tokunaga Y, Takahashi T, et al. Osteotropic drug delivery system (ODDS) based on bisphosphonic prodrug. V: biological disposition and targeting characteristics of osteotropic estradiol. Biol Pharm Bull 1997; 20(11): 1183–7PubMedCrossRefGoogle Scholar
  40. 40.
    Herczegh P, Buxton TB, McPherson III JC, et al. Osteoadsorptive bisphosphonate derivatives of fluoroquinolone antibacterials. J Med Chem 2002; 45(11): 2338–41PubMedCrossRefGoogle Scholar
  41. 41.
    Klenner T, Valenzuela-Paz P, Keppler BK, et al. Cisplatin-linked phosphonates in the treatment of the transplantable osteosarcoma in vitro and in vivo. Cancer Treat Rev 1990; 17 (2–3): 253–9PubMedCrossRefGoogle Scholar
  42. 42.
    Klenner T, Wingen F, Keppler BK, et al. Anticancer-agent-linked phosphonates with antiosteolytic and antineoplastic properties: a promising perspective in the treatment of bone-related malignancies? J Cancer Res Clin Oncol 1990; 116(4): 341–50PubMedCrossRefGoogle Scholar
  43. 43.
    Klenner T, Wingen F, Keppler B, et al. Therapeutic efficacy of two different cytostatic-linked phosphonates in combination with razoxane in the transplantable osteosarcoma of the rat. Clin Exp Metastasis 1990; 8(4): 345–59PubMedCrossRefGoogle Scholar
  44. 44.
    Sturtz G, Couthon H, Fabulet O, et al. Synthesis of gembisphosphonic methotrexate conjugates and their biological response towards Walkers’s osteosarcoma. Eur J Med Chem 1993; 28: 899–903CrossRefGoogle Scholar
  45. 45.
    Hosain F, Spencer RP, Couthon HM, et al. Targeted delivery of antineoplastic agent to bone: biodistribution studies of technetium-99m-labeled gem-bisphosphonate conjugate of methotrexate. J Nucl Med 1996; 37(1): 105–7PubMedGoogle Scholar
  46. 46.
    Serafini AN. Systemic metabolic radiotherapy with samarium-153 EDTMP for the treatment of painful bone metastasis. Q J Nucl Med 2001; 45(1): 91–9PubMedGoogle Scholar
  47. 47.
    Lamb HM, Faulds D. Samarium 153Sm lexidronam. Drugs Aging 1997; 11(5): 413–8PubMedCrossRefGoogle Scholar
  48. 48.
    Eary JF, Collins C, Stabin M, et al. Samarium-153-EDTMP biodistribution and dosimetry estimation. J Nucl Med 1993; 34(7): 1031–6PubMedGoogle Scholar
  49. 49.
    Lewington VJ. Cancer therapy using bone-seeking isotopes. Phys Med Biol 1996; 41(10): 2027–42PubMedCrossRefGoogle Scholar
  50. 50.
    Mundy GR. Pathogenesis of osteoporosis and challenges for drug delivery. Adv Drug Deliv Rev 2000; 42(3): 165–73PubMedCrossRefGoogle Scholar
  51. 51.
    Gambrell Jr RD. The menopause: benefits and risks of estrogen-progestogen replacement therapy. Fertil Steril 1982; 37(4): 457–74PubMedGoogle Scholar
  52. 52.
    Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995; 332(24): 1589–93PubMedCrossRefGoogle Scholar
  53. 53.
    Pardridge WM, Mietus LJ. Transport of steroid hormones through the rat blood-brain barrier: primary role of albumin-bound hormone. J Clin Invest 1979; 64(1): 145–54PubMedCrossRefGoogle Scholar
  54. 54.
    Orme MW, Labroo VM. Synthesis of β-estradiol-3-benzoate-17-(succinyl-12A-tetracycline): a potential bone-seeking estrogen. Bioorg Med Chem Lett 1994; 4(11): 1375–80CrossRefGoogle Scholar
  55. 55.
    Yokogawa K, Miya K, Sekido T, et al. Selective delivery of estradiol to bone by aspartic acid oligopeptide and its effects on ovariectomized mice. Endocrinology 2001; 142(3): 1228–33PubMedCrossRefGoogle Scholar
  56. 56.
    Sekido T, Sakura N, Higashi Y, et al. Novel drug delivery system to bone using acidic oligopeptide: pharmacokinetic characteristics and pharmacological potential. J Drug Target 2001; 9(2): 111–21PubMedCrossRefGoogle Scholar
  57. 57.
    Uludag H, Kousinioris N, Gao T, et al. Bisphosphonate conjugation to proteins as a means to impart bone affinity. Biotechnol Prog 2000; 16(2): 258–67PubMedCrossRefGoogle Scholar
  58. 58.
    Uludag H, Gao T, Wohl GR, et al. Bone affinity of a bisphosphonate-conjugated protein in vivo. Biotechnol Prog 2000; 16(6): 1115–8PubMedCrossRefGoogle Scholar
  59. 59.
    Uludag H, Yang J. Targeting systemically administered proteins to bone by bisphosphonate conjugation. Biotechnol Prog 2002; 18(3): 604–11PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2003

Authors and Affiliations

  1. 1.Biopharmaceutical and Pharmacokinetic Research LaboratoriesFujisawa Pharmaceutical CompanyYodogawa-ku, OsakaJapan
  2. 2.Manufacturing TechnologyFujisawa Pharmaceutical CompanyOsakaJapan

Personalised recommendations